查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1466262

连续生物加工市场：按产品、製程、应用、业务规模、最终用户划分 - 2024-2030 年全球预测

Continuous Bioprocessing Market by Product (Bioreactors, Cell Culture Media & Reagent, Centrifuges), Process (Downstream Bioprocess, Upstream Bioprocess), Application, Scale of Operation, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年连续生物加工市场规模为2.3344亿美元，2024年将达2.8242亿美元，2030年将达9.0223亿美元，复合年增长率为21.30%。

连续生物加工代表了疫苗、单株抗体和治疗性蛋白质等生物製药生产的模式转移。连续生物加工允许材料和产品在整个生产週期中不间断地流动，从而提高效率、品管和可扩展性，这与传统的批量加工不同，传统的批量加工可以预期在单独的步骤中加工固定数量的产品。製药业正在不断发展，政府对该领域的支持是连续生物加工成长的关键驱动力。超批量加工和一次性技术的引入带来的好处不断增加，以及对生物製药生产的持续需求，正在刺激连续生物加工技术的采用。相较之下，高昂的设备成本、操作困难以及对製程变化的担忧对生物製程的持续采用提出了挑战。此外，必须考虑监管因素，因为连续生物过程可能需要新的验证策略才能符合卫生当局製定的严格标准。然而，一些市场供应商正在投资研发，以解决连续生物加工技术中的许多营运挑战，并为进一步的市场扩张做好准备。此外，灌注的采用与一次性设备相关，基质细胞製造的连续生物製程方法的市场开拓预计将在未来几年显着促进整体市场成长。

主要市场统计
基准年[2023] 2.3344亿美元
预测年份 [2024] 2.8242亿美元
预测年份 [2030] 9.0223亿美元
复合年增长率（%） 21.30%

产物：在重组蛋白的大规模生产中越来越偏好反应器

反应器是发生生物反应的容器，特别适用于培养细菌、酵母菌和哺乳动物细胞等生物。这对于扩大生物製程规模至关重要。细胞培养基和试剂列出了生物过程中细胞生长和产物表现所需的必需营养素。离心机用于根据混合物的密度分离混合物的成分。在生物加工中，它对于细胞澄清和产品回收至关重要。层析法系统用于精製生物产品。连续层析法技术，包括模拟移动床 (SMB) 系统，可提供高生产率和层析法介质的高效使用，从而降低耗材成本。过滤系统对于製程流体的灭菌和澄清至关重要，确保去除杂质和污染物。培养箱和摇床对于优化细胞培养生长条件、控制温度、湿度和搅拌至关重要。混合系统确保反应器和储存罐内的均匀性，并影响细胞生长、营养分布和产物形成的一致性。相较之下，连续反应器可以不间断地运作，确保产品品质一致并可能降低製造成本，而连续离心机可以不间断地加工生物产品，提高效率和一致性。

流程：由于效率和产能的提高，上游工程的使用增加

上游工程构成生物生产的初始阶段，涉及适合微生物、植物和哺乳动物细胞生长和繁殖的环境的开发和维护。此步骤通常包括培养基製备、细胞培养、细胞储存和初次回收。在上游工程之后，下游生物过程精製并製备这些生物产品以供最终使用或进一步配製。由于生物製品固有的复杂性和多样性，下游加工通常需要复杂的分离和精製技术，例如离心、过滤和层析法。上游和下游生物过程对于最终产品的生产率和品质都很重要。然而，它们的主要目的、复杂性和挑战差异很大。上游着重于培养细胞培养和增殖的最佳环境，下游着重于所得产物的精製和精製。

应用：在疫苗产业广泛使用连续生物製程来改善公众健康

细胞和基因治疗中的连续生物加工利用尖端技术来产生个人化治疗。该领域的优势包括减少批次差异、提高可扩展性以及提高产品一致性。连续生产单株抗体的製程可减少劳动力和设施占地面积，并实现即时品质监控，提高生产率和成本效益。在疫苗行业，由于大流行期间需要快速开发和部署以及流感等季节性疫苗的生产，对连续生物加工的兴趣正在增加。连续生物加工可以显着缩短开发时间并提高对公共卫生需求的应对力。相较之下，连续加工提供了提高疫苗加工集约化、稳定性和产量的机会。

业务规模：扩大连续生物加工在临床业务的应用

临床业务对于连续生物加工至关重要，对开发的生技药品的功效和品质具有至关重要的影响。它涵盖广泛的活动，从早期临床试验到遵守药物安全性和有效性监管指南的程序。连续生物加工的商业运作围绕着大规模实施该工艺以实现商业化和销售的实用性。目标是扩大生产规模并确保一致的品质、成本效益和法规遵循。连续生物加工为简化生物製药生产提供了一种有前途的方法，但其实施在规模、临床和商业业务存在很大差异。

最终用户：连续生物加工在 CDMO 中的作用非常重要，它优先考虑弹性和增强向客户提供的服务。

学术和研究机构通常专注于连续生物加工的基础科学和概念验证研究。这些机构透过进行创新研究并经常与产业合作伙伴合作，在推动技术进步方面发挥着至关重要的作用。受託製造厂商描述了向製药和生物技术公司外包开发和製造服务。它们是药品供应链不可或缺的一部分，越来越多地采用连续生物加工来实现产品差异化并提高成本效率。製药和生物技术公司是推动连续生物製程商业性实施的主要最终用户。另一方面，学术和研究机构透过出版物、专利和熟练专业人员的培训为连续生物加工做出贡献。与研究机构不同，CDMO 投资于可扩展且适应性强的技术，可以支援多种产品和流程，从而为客户优化上市时间。与学术机构和 CDMO 不同，製药和生物技术公司既进行内部产品开发又进行商业生产。

区域洞察

在美洲地区，对生物製造创新的浓厚兴趣、对生物技术领域的大量投资以及鼓励先进製造技术的法规环境正在推动连续生物加工的采用。随着主要製药公司和生物风险公司寻求更高效、更具成本效益和可扩展的製造工艺，连续生物加工代表了一种竞争优势。此外，强大的技术基础设施和熟练劳动力的存在正在促进美洲从传统批量工艺向连续方法的转变。此外，在欧洲、中东和非洲，高昂的营运成本和严格的监管标准导致公司采用连续生物製程来降低成本并提高生技药品的品质。欧洲製药业以注重创新和永续性而闻名，这反映在快速成长的生物相似药市场。此外，中东和非洲也开始采用此类流程。由于对生物製药的需求不断增长以及药品生产能力本地化的努力，连续生物加工预计将在该地区增长。在亚太地区，由于生物製药行业的快速扩张和全球竞争的需要，连续生物加工的采用正在迅速增加。越来越多的患者需要高品质的生技药品，生物技术公司不断增加投资，并支持政府旨在提高生物製造能力的措施。一些国家对实施连续流程以加快药物开发和製造时间表、减少製造足迹并节省成本，同时遵守国际品质标准表现出了浓厚的兴趣。

FPNV定位矩阵

FPNV定位矩阵对于评估连续生物加工市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对连续生物加工市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、碎片化主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.连续生物加工市场的市场规模与预测是多少？

2. 在连续生物加工市场的预测期内，我们应该考虑投资哪些产品和应用？

3.连续生物加工市场的技术趋势和法规结构是什么？

4.连续生物加工市场主要供应商的市场占有率为何？

5. 进入连续生物加工市场的适当型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 生物製药需求增加以及政府对该行业的支持
      • 采用批量处理和一次性技术带来的更多好处
      • 工业4.0的到来以及自动化数位化的趋势
    • 抑制因素
      • 连续生物加工的严格法规和高昂的设备成本
    • 机会
      • 采用与一次性设备结合的灌注
      • 开发基质细胞生产的连续生物製程方法
    • 任务
      • 操作困难和流程变更问题
  • 市场区隔分析
    • 产品：反应器在大规模重组蛋白生产中日益普及
    • 流程：由于效率和产能的提高，上游流程的使用增加
    • 应用：透过在疫苗产业广泛使用连续生物製程来改善公众健康
    • 业务规模：扩大连续生物加工在临床业务的应用
    • 最终用户：连续生物加工发挥关键作用，因为 CDMO 优先考虑弹性和增强的客户服务
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章连续生物加工市场：副产品

  • 介绍
  • 反应器
  • 细胞培养基和试剂
  • 离心机
  • 层析法系统
  • 过滤系统
  • 培养箱和摇床

第七章连续生物加工市场：依製程分类

  • 介绍
  • 下游生物过程
  • 上游生物工艺

第八章连续生物加工市场：依应用分类

  • 介绍
  • 细胞/基因治疗
  • 单株抗体
  • 疫苗

第九章连续生物製程市场：依业务规模

  • 介绍
  • 临床
  • 商业的

第十章连续生物加工市场：依最终用户分类

  • 介绍
  • 学术研究所
  • 合约开发和製造组织
  • 製药和生物技术公司

第十一章美洲连续生物处理市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太连续生物加工市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的连续生物加工市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

第15章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-033F7A232457

[189 Pages Report] The Continuous Bioprocessing Market size was estimated at USD 233.44 million in 2023 and expected to reach USD 282.42 million in 2024, at a CAGR 21.30% to reach USD 902.23 million by 2030.

Continuous bioprocessing represents a paradigm shift in the production of biopharmaceutical products, such as vaccines, monoclonal antibodies, or therapeutic proteins. Continuous bioprocessing allows for the uninterrupted flow of materials and products through the production cycle, offering potential improvements in efficiency, quality control, and scalability, unlike traditional batch processing, which processes a fixed volume of products in discrete steps. Pharmaceutical industries are advancing, and government support for the sector is the principal driver of growth for continuous bioprocessing. Increased benefits of over-batch processing & uptake of single-use technology and the continued demand for the production of biopharmaceutical products are spurring the adoption of continuous bioprocessing technologies. In contrast, high equipment costs, operational difficulties, and process change concerns pose a challenge to adopting a continuous bioprocess. In addition, regulatory considerations must be managed, as continuous bioprocessing may necessitate new validation strategies to comply with the stringent standards set by health authorities. However, several market vendors invest in research and development to address many operational challenges in the continuous bioprocessing technologies and further chart to expand the market. Moreover, the adoption of perfusion is associated with single-use equipment, and the development of a continuous bioprocessing approach to stromal cell manufacturing is expected to enhance overall market growth in the coming years significantly.

KEY MARKET STATISTICS
Base Year [2023] USD 233.44 million
Estimated Year [2024] USD 282.42 million
Forecast Year [2030] USD 902.23 million
CAGR (%) 21.30%

Product: Growing preference for bioreactors in large-scale production of recombinant proteins

Bioreactors are vessels in which biological reactions are carried out, especially for culturing organisms such as bacteria, yeast, and mammalian cells. They are crucial for scaling up bioprocessing. Cell culture media and reagents provide the essential nutrients required for cell growth and product expression in bioprocessing. Centrifuges are utilized to separate components of a mixture based on their density. In bioprocessing, they are essential for cell clarification and product recovery. Chromatography systems are employed for the purification of biological products. Continuous chromatography technologies, including simulated moving bed (SMB) systems, offer higher productivity and better utilization of chromatography media, reducing the cost of consumables. Filtration systems are imperative for sterilizing and clarifying process fluids, warranting the removal of impurities and contaminants. Incubators and shakers are vital for optimizing growth conditions for cell cultures, providing control over temperature, humidity, and agitation. Mixing systems ensure homogeneity in bioreactors and holding tanks, influencing cell growth, nutrient distribution, and product formation consistency. In comparison, continuous bioreactors operate without interruption, ensuring consistent product quality and potentially lower manufacturing costs, and continuous centrifuges allow for the uninterrupted processing of bioproducts, enhancing efficiency and consistency.

Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity

Upstream processing, constituting the initial steps of bioproduction, involves developing and maintaining a suitable environment for the growth and multiplication of microbial cells, plant, or mammalian cells. This phase often includes media preparation, cell culture, cell preservation, and primary recovery. Downstream bioprocessing, which follows the upstream step, involves purifying these biological products, and preparing them for their final use or further formulation. Due to inherent complexity and diversity of biological products, downstream processes typically entail complex separation and purification techniques, including centrifugation, filtration, chromatography and more. Both upstream and downstream bioprocessing are critical for both productivity and quality of end products. However, they differ significantly in their chief objectives, complexities, and challenges. Upstream focuses on fostering an optimal environment for cell culture and propagation, while downstream is centered around the purification and refinement of the resultant product.

Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health

Continuous bioprocessing in cell and gene therapies involves using cutting-edge techniques to manufacture personalized treatments. This sector benefits from reduced batch-to-batch variability, enhanced scalability, and improved product consistency. Continuous processes for manufacturing monoclonal antibodies increase productivity and cost-effectiveness due to reduced labor and facility footprint and the potential for real-time quality monitoring. The vaccine industry is experiencing a growing interest in continuous bioprocessing, given the need for rapid development and deployment during pandemics and the production of seasonal vaccines, such as those for influenza. Continuous bioprocessing can substantially shorten development times and improve responsiveness to public health needs. In comparison, continuous processing offers opportunities for enhancing process intensification, stability, and throughput for vaccines.

Scale of Operation: Growing application of continuous bioprocessing in the clinical operations

Clinical operations are integral to continuous bioprocessing, pivotally influencing the efficacy and quality of the developed biologics. It encapsulates a broad range of activities, from early-stage clinical trials to procedures adhering to regulatory guidelines for the safety and efficacy of medicinal products. Commercial operations in continuous bioprocessing revolve around the practicality of implementing the processes on a large scale for commercialization and sale. It's about scaling up production and ensuring consistent quality, cost-effectiveness, and regulatory compliance. While continuous bioprocessing presents a promising approach to streamline biopharmaceutical production, its implementation differs widely across the scale, clinical, and commercial operations.

End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients

Academic and research institutes often focus on fundamental science and proof-of-concept studies in continuous bioprocessing. They are crucial in advancing technology by conducting innovative research, often collaborating with industry partners. Contract development & manufacturing organizations offer outsourced development and manufacturing services to pharmaceutical and biotech companies. They are an integral part of the pharmaceutical supply chain and increasingly incorporate continuous bioprocessing to differentiate their offerings and improve cost efficiencies. Pharmaceutical and biotechnology companies are the primary end-users driving the commercial implementation of continuous bioprocessing. In comparison, academic and research institutes contribute to the continuous bioprocessing through publications, patents, and training of skilled professionals. In contrast to research institutes, CDMOs invest in scalable and adaptable technologies that can cater to multiple products and processes, optimizing time-to-market for their clients. Pharmaceutical & biotechnology companies carry out both in-house product development and commercial production, unlike academic institutes or CDMOs.

Regional Insights

In the American region, the adoption of continuous bioprocessing is driven by a strong focus on innovation in biomanufacturing, significant investments in the biotech sector, and a regulatory environment encouraging advanced production techniques. With major pharmaceutical companies and biotech startups striving to achieve more efficient, cost-effective, and scalable manufacturing processes, continuous bioprocessing offers a competitive advantage. Additionally, the presence of a robust technological infrastructure and highly skilled workforce has facilitated the transition from traditional batch processes to continuous approaches in the Americas. Furthermore, in EMEA, high operational costs and stringent regulatory standards have pushed companies to adopt continuous bioprocessing to reduce costs and enhance the quality of biologics. The European pharmaceutical landscape is known for its strong emphasis on innovation and sustainability, which is further reflected in its rapidly growing biosimilar market, where continuous bioprocessing delivers substantial benefits in terms of production agility and speed to market. Additionally, adopting such processes is nascent in the Middle East and Africa. In this region, the continuous bioprocessing is expected to grow by the increasing need for biologics and efforts to localize pharmaceutical production capabilities. The APAC region has seen a surge in adopting continuous bioprocessing due to its rapidly expanding biopharmaceutical sector and the need to compete globally. A growing patient population needs high-quality biologics, increasing investments from players in biotechnology, and supportive government initiatives aiming to boost biomanufacturing capabilities. Several countries have demonstrated significant interest in incorporating continuous processes to accelerate drug development and production timelines, reduce manufacturing footprints, and enable cost savings, all while complying with international quality standards.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Continuous Bioprocessing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Continuous Bioprocessing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Continuous Bioprocessing Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, 3M Company, Adolf Kuhner AG, bbi-biotech GmbH, Belach Bioteknik AB, Bio-Rad Laboratories, Inc., Bionet Servicios Tecnicos S.L., Colder Products Company, Danaher Corporation, Esco Aster Pte Ltd., Esco VacciXcell, FiberCell Systems Inc., Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GEA Group, Getinge AB, Infors AG, Merck KGaA, Repligen Corporation, Sartorius AG, simAbs NV, Suzhou Transcenta Therapeutics Co., Ltd., Thermo Fisher Scientific Inc., Watson-Marlow Fluid Technology Group, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Continuous Bioprocessing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Bioreactors
    • Cell Culture Media & Reagent
    • Centrifuges
    • Chromatography System
    • Filtration Systems
    • Incubators & Shakers
  • Process
    • Downstream Bioprocess
    • Upstream Bioprocess
  • Application
    • Cell & Gene Therapy
    • Monoclonal Antibodies
    • Vaccines
  • Scale of Operation
    • Clinical Operations
    • Commercial Operations
  • End-User
    • Academic & Research Institutes
    • Contract Development & Manufacturing Organizations
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Continuous Bioprocessing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Continuous Bioprocessing Market?

3. What are the technology trends and regulatory frameworks in the Continuous Bioprocessing Market?

4. What is the market share of the leading vendors in the Continuous Bioprocessing Market?

5. Which modes and strategic moves are suitable for entering the Continuous Bioprocessing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for biopharmaceuticals & government support for the industry
      • 5.1.1.2. Increased benefits over batch processing & uptake of single-use technology
      • 5.1.1.3. Advent of industry 4.0 & trend towards automation & digitization
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations for continuous bioprocessing coupled with high equipment cost
    • 5.1.3. Opportunities
      • 5.1.3.1. Adoption of perfusion associated with single-use equipment
      • 5.1.3.2. Development of a continuous bioprocessing approach to stromal cell manufacturing
    • 5.1.4. Challenges
      • 5.1.4.1. Issues with operational difficulties and process changes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing preference for bioreactors in large-scale production of recombinant proteins
    • 5.2.2. Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity
    • 5.2.3. Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health
    • 5.2.4. Scale of Operation: Growing application of continuous bioprocessing in the clinical operations
    • 5.2.5. End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Continuous Bioprocessing Market, by Product

  • 6.1. Introduction
  • 6.2. Bioreactors
  • 6.3. Cell Culture Media & Reagent
  • 6.4. Centrifuges
  • 6.5. Chromatography System
  • 6.6. Filtration Systems
  • 6.7. Incubators & Shakers

7. Continuous Bioprocessing Market, by Process

  • 7.1. Introduction
  • 7.2. Downstream Bioprocess
  • 7.3. Upstream Bioprocess

8. Continuous Bioprocessing Market, by Application

  • 8.1. Introduction
  • 8.2. Cell & Gene Therapy
  • 8.3. Monoclonal Antibodies
  • 8.4. Vaccines

9. Continuous Bioprocessing Market, by Scale of Operation

  • 9.1. Introduction
  • 9.2. Clinical Operations
  • 9.3. Commercial Operations

10. Continuous Bioprocessing Market, by End-User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Contract Development & Manufacturing Organizations
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Continuous Bioprocessing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Continuous Bioprocessing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Continuous Bioprocessing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
    • 14.3.2. Sartorius and Repligen Launch Integrated Bioreactor System
    • 14.3.3. 3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology
  • 14.4. Strategy Analysis & Recommendation

15. Competitive Portfolio

  • 15.1. Key Company Profiles
  • 15.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CONTINUOUS BIOPROCESSING MARKET RESEARCH PROCESS
  • FIGURE 2. CONTINUOUS BIOPROCESSING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CONTINUOUS BIOPROCESSING MARKET DYNAMICS
  • FIGURE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 20. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 25. CONTINUOUS BIOPROCESSING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 26. CONTINUOUS BIOPROCESSING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONTINUOUS BIOPROCESSING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 51. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 52. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 53. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 56. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 57. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 62. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 63. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 64. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 65. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 68. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 69. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 74. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 75. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 78. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 79. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 84. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 85. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 86. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 87. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 88. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 89. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 94. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 95. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 98. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 99. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 102. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 103. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 104. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 105. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 108. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 109. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 126. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 128. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 132. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 138. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 139. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 142. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 143. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 148. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 149. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 152. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 153. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 158. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 159. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 162. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 163. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 166. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 167. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 168. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 169. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 172. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 173. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 178. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 179. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 182. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 183. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 184. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 186. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 188. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 192. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 198. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 199. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 200. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 201. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 202. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 203. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 204. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 208. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 212. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 214. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 215. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 218. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 219. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 220. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 221. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 222. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 223. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 228. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 229. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 232. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 233. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 234. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 235. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 236. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 237. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 238. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 239. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 242. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 243. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 244. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 257. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 258. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 259. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 260. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 261. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 264. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 265. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 270. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 271. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 274. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 275. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 276. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 277. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 280. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 281. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 284. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 285. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 286. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 287. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 290. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 291. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 292. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 293. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 294. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 295. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 300. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 301. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 304. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 305. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 306. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 307. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 310. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 311. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 314. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 315. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 316. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 317. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 318. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 319. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 320. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 321. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
  • TABLE 324. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
  • TABLE 325. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 326. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
  • TABLE 330. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 332. NETHERLANDS CONTINUOUS BIOPROCESSING MA